Cargando…
Fixed-Dose Versus Off-Label Combination of Isosorbide Dinitrate Plus Hydralazine Hydrochloride: Retrospective Propensity-Matched Analysis in Black Medicare Patients with Heart Failure
INTRODUCTION: Based upon the findings of the African-American Heart Failure Trial, the US Food and Drug Administration approved the fixed-dose combination of isosorbide dinitrate (ISDN) and hydralazine hydrochloride (HYD) (FDC-ISDN/HYD) as a new drug for treatment of heart failure (HF) in self-ident...
Autores principales: | Ofili, Elizabeth, Anand, Inder, Williams, Richard Allen, Akinboboye, Ola, Xu, Liou, Puckrein, Gary |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5565652/ https://www.ncbi.nlm.nih.gov/pubmed/28707284 http://dx.doi.org/10.1007/s12325-017-0584-x |
Ejemplares similares
-
Isosorbide dinitrate-hydralazine combination therapy in African Americans with heart failure
por: Echols, Melvin R, et al.
Publicado: (2006) -
Eco-friendly estimation of isosorbide dinitrate and hydralazine hydrochloride using Green Analytical Quality by Design-based UPLC Method
por: Chanduluru, Hemanth Kumar, et al.
Publicado: (2021) -
Hydralazine–Isosorbide Dinitrate Use in Patients With End-Stage Kidney Disease on Dialysis
por: Mavrakanas, Thomas A., et al.
Publicado: (2022) -
Underuse of hydralazine and isosorbide dinitrate for heart failure in patients of African ancestry: a cross‐European survey
por: Brewster, Lizzy M.
Publicado: (2019) -
Coronary MRI with induced vasodilation using isosorbide dinitrate
por: Hu, Peng, et al.
Publicado: (2009)